Background The clinical use of doxorubicin and trastuzumab in HER2-positive breast cancer is limited by significant cardiotoxicity. Sodium-glucose cotransporter 2 inhibitors (SGLT2is), such as canagliflozin and dapagliflozin, have demonstrated cardiovascular protection in diabetes and heart failure, and emerging evidence suggests potential antineoplastic activity. Whether SGLT2is can simultaneously enhance antitumor…